We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Tcr2 Therapeutics Inc (TCRR) USD0.0001

Sell:$4.99 Buy:$5.01 Change: $0.22 (4.21%)
Market closed |  Prices as at close on 3 December 2021 | Switch to live prices |
Sell:$4.99
Buy:$5.01
Change: $0.22 (4.21%)
Market closed |  Prices as at close on 3 December 2021 | Switch to live prices |
Sell:$4.99
Buy:$5.01
Change: $0.22 (4.21%)
Market closed |  Prices as at close on 3 December 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

TCR2 Therapeutics Inc. is a clinical-stage immunotherapy company developing T cell therapies for patients suffering from cancer. The Company's T cell receptor (TCR) Fusion Construct T cells (TRuC-T cells) specifically recognize and kill cancer cells by harnessing the entire T cell receptor (TCR) signaling complex. Its lead TRuC-T cell, which targets solid tumors is gavocabtagene autoleucel (gavo-cel). It is conducting Phase I/II clinical trial for gavo-cel to treat patients with non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma and cholangiocarcinoma. Its lead TRuC-T cell, which targets hematological malignancies is TC-110. It is conducting Phase I/II clinical trial for TC-110 to treat patients with adult acute lymphoblastic leukemia (aALL) and with aggressive or indolent non-Hodgkin's lymphoma (NHL). Its other product candidates include TC-510, IL-15, CD70 and GPC3, which focuses on solid tumors.

Contact details

Address:
100 Binney St
CAMBRIDGE
02142-1096
United States
Telephone:
+1 (617) 9495200
Website:
www.tcr2.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
TCRR
ISIN:
US87808K1060
Market cap:
$196.84 million
Shares in issue:
38.22 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Garry Menzel
    President, Chief Executive Officer, Director
  • Mayur Somaiya
    Chief Financial Officer
  • Angela Justice
    Chief People Officer
  • Robert Hofmeister
    Chief Scientific Officer
  • Alfonso Cardama
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.